

. ...

op ajanta pharma limited

Ajanta House, Charkop, Kandivli West, Mumbai 400 067 India

T +91 22 6606 1000 F +91 22 6606 1200 E info@ajantapharma.com W www.ajantapharma.com

8th January 2020

Mumbai – 400001	Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
BSE LIMITED	National Stock Exchange of India,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no.
Dalal Street,	C/1, G Block, Bandra Kurla Complex,

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find Compliance Report on Corporate Governance (CG) for the quarter ended on 31st December 2019.

Thanking You,

Yours faithfully,

GAURANG SHAH AVP - Legal & Company Secretary

Encl.: a/a

Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

1. Name of Listed Entity : Ajanta

2. Quarter ending

: Ajanta Pharma Limited : 31st December 2019

I. Composition of Board of Directors

C	Name of the	PAN\$		Initial Data	Data of Da	Data -f	-	Data	<u> </u>			
C			Category	Initial Date	Date of Re-	Date of	Tenure		of No of	No of	Number of	No of post
	Director	& DIN	(Chairperson	of	appoint	Cessation	*	Birth	Directo	Indepen	membershi	of
			/Executive/	Appointme	ment				rship	dent	ps in Audit/	Chairperso
			Non-	l nt					in	Director	Stakeholder	n in Audit/
			Executive/					-	listed	s in	Committee	Stakeholde
			independent						entitie	listed	(s)	r
			/						s	entities	including	Committee
			Nominee) &						includi	includin	this listed	held in
									ng this	g this	entity	listed
									listed	listed	(Refer	entities
									entity	entity	Regulation	including
									(in	[in	26(1) of	this listed
									refere	referenc	Listing	entity
									nce to	e to	Regulations	(Refer
									Regula	proviso)	Regulation
									tion	to		26(1) of
									17A (1)	regulati		Listing
		ſ								on 17A		Regulations
		l								(1)])
	SAME AS PREVIOUS QUARTER											

II. Composition of Committees Name of Committee Whether Regular Name Category (Chairperson/Executive/Non Executive/Indepen of Date Date of of chairperson appointed Committee dent/Nominee)\$ Appointment Cessation members SAME AS PREVIOUS QUARTER

	Date(s) of Meeting (if any) in the relevant quarter		Number Directors present *	of Number of Independent directors present *	Maximum gap between any two consecutive (in number of days)
31 st July 2019	5 th November 2019	Yes	7	4	96

IV. Meeting of Committees									
Date(s) of meeting of the Whether re		umber of	Number of	Date(s) of meeting of	Maximum gap between any two				
committee in the relevant of Quorum m		irectors	Independent	the committee in the	consecutive meetings in number				
quarter	pr	resent *	directors present *	previous quarter	of days*				
5 th November 2019 Yes	4		3	31 st July 2019	96				
* This information has to be mandatorily be given for audit committee, for rest of the committee giving this information is optional									
**to be filled in only for the current quarter meetings									
V. Related Party Transactions									
Subject Compliance status (Yes/No/NA) refer note below									
Whether prior approval of audit committee obtained Yes									
Whether shareholder approval obtained for r	Whether shareholder approval obtained for material RPT Not Applicable								
Note: Material RPTs are with the Wholly Owned subsidiary and are in the ordinary course of									
business and on arm's length basis. Shareholders' approval is not required as Regulation 23(2)									
23(3) & 23(4) of Listing Regulations are not applicable.									
Whether details of RPT entered into pursuant to omnibus Yes									
approval have been reviewed by Audit Committee									
Note :				-					
1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions,									
the words "N A " may be indicated	isting Regulation	ons, res may	be indicated. Similarly	, in case the Listed Entity	has no related party transactions,				
the words "N.A." may be indicated. 2. If status is "No" details of non-compliance may be given here.									
VI. Affirmations									
1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.									
2. The composition of the following commit	tees is in term	is of SEBI(Listing	g Obligations and Disclo	osure Requirements) Regula	ations, 2015				
a. Audit Committee									
b. Nomination & Remuneration committee									
c. Stakeholders relationship committee									
d. Risk management committee (applicable to the top 500 listed entities) : Applicable									
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.									
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.									
5. This report will be placed before Board of Directors at the ensuing Board meeting.									
Name & Designation : Gaurang Shah									
M									
Company Secretary / Compliance Officer / Managing Director / CEO / CFO : Company Secretary & Compliance Officer									